Evidence map›Paper›PMID 38796633›Full record

ArticleBone marrow transplantation2024

Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era.

Toshiki Terao, Ken-Ichi Matsuoka, Shigeo Fuji, Shunto Kawamura, Takashi Toya, Noriko Doki, Naoyuki Uchida, Masatsugu Tanaka, Takahiro Fukuda, Masashi Sawa and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Toshiki TeraoDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan. tarao.toshiki.0127@gmail.com.ORCID http://orcid.org/0000-0002-6728-3346
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.ORCID http://orcid.org/0000-0001-7955-8266
Shigeo FujiDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.ORCID http://orcid.org/0000-0001-5118-7950
Shunto KawamuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Takashi ToyaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7436-972X
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8661-3179
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5952-5926
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Aichi, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Tetsuya NishidaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Aichi, Japan.
Hiroyuki OhigashiDepartment of Hematology, Hokkaido University Hospital, Hokkaido, Japan.
Yumiko MaruyamaDepartment of Hematology, University of Tsukuba Hospital, Ibaraki, Japan.
Shin-Ichiro FujiwaraDivision of Hematology, Jichi Medical University, Tochigi, Japan.ORCID http://orcid.org/0000-0002-4523-2994
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0002-4866-9307
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Hokkaido, Japan.ORCID http://orcid.org/0000-0002-3631-244X
Fumihiko IshimaruJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan.ORCID http://orcid.org/0000-0003-4404-2870
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6704-3633
Masao OgataDepartment of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.ORCID http://orcid.org/0000-0002-4896-5878
Kimikazu YakushijinDepartment of Medical Oncology and Hematology, Kobe University Hospital, Hyogo, Japan.ORCID http://orcid.org/0000-0003-2511-7857
Hideki NakasoneDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0001-5812-9315

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of letermovir (LTV)-an anti-cytomegalovirus (CMV) drug-on human herpesvirus-6 (HHV-6) encephalitis is unclear. We hypothesized that LTV prophylaxis may increase the incidence of HHV-6 encephalitis by reducing anti-CMV therapies after allogeneic hematopoietic stem cell transplantation (HSCT). To evaluate the association between HHV-6 encephalitis and antiviral prophylaxis, 7985 adult patients from a nationwide registry who underwent their first HSCT between January 2019 and December 2021 were analyzed. The incidence of HHV-6 encephalitis on day 100 after HSCT was 3.6%; 11.5% for the broad-spectrum antiviral group (foscarnet, ganciclovir, or valganciclovir); 2.8% for the LTV group, and 3.8% for the other antiviral group (p < 0.001). These differences persisted when cord blood transplantation (CBT) was analyzed separately (14.1%, 5.9%, and 7.4%, p < 0.001). In the multivariate analysis, CBT (hazard ratio [HR]: 2.90), broad-spectrum antiviral prophylaxis (HR: 1.91), and grade II-IV acute graft-versus-host disease requiring systemic corticosteroids (HR: 2.42) were independent risk factors for encephalitis (all p < 0.001). The findings of this large modern database study indicate that broad-spectrum antiviral prophylaxis, rather than LTV prophylaxis, is paradoxically associated with HHV-6 encephalitis in the LTV era. This paradoxical finding needs to be further explored in future studies.

Indexed as

Antiviral AgentsEncephalitis, ViralHematopoietic Stem Cell TransplantationHerpesvirus 6, HumanRoseolovirus InfectionsAcetatesAdultFemaleHumansMaleMiddle AgedQuinazolinesTransplantation, HomologousTriazolesAcetatesAntiviral AgentsletermovirQuinazolinesTriazoles

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.